Stefan Ehehalt1,2, Susanna Wiegand3, Antje Körner4, Roland Schweizer2, Klaus-Peter Liesenkötter5, Carl-Joachim Partsch6, Gunnar Blumenstock7, Ulrike Spielau4, Christian Denzer8, Michael B Ranke2, Andreas Neu2, Gerhard Binder2, Martin Wabitsch8, Wieland Kiess4, Thomas Reinehr9. 1. Public Health Department of Stuttgart, Department of Pediatrics, Dental Health Care, Health Promotion and Social Services, Schloßstraße 91, 70176, Stuttgart, Germany. 2. Pediatric Endocrinology and Diabetes, University Children's Hospital, University of Tübingen, Hoppe-Seyler-Str. 1, 72076, Tübingen, Germany. 3. Department of Pediatric Endocrinology and Diabetes, Charité Children's Hospital, Universitätsmedizin Berlin, Augustenburger Platz 1, D-13353, Berlin, Germany. susanna.wiegand@charite.de. 4. Hospital for Children and Adolescents, Department of Women and Child Health, University Hospitals, University of Leipzig, Liebigstraße 20a, D-04103, Leipzig, Germany. 5. Endokrinologikum Berlin am Gendarmenmarkt, Friedrichstraße 76, Jägerstraße 61, 10117, Berlin, Germany. 6. Endokrinologikum Hamburg, Lornsenstraße 4-6, 22767, Hamburg, Germany. 7. Department of Clinical Epidemiology and Applied Biometry, University of Tübingen, Silcherstraße 5, 72076, Tübingen, Germany. 8. Division of Pediatric Endocrinology and Diabetes, Interdisciplinary Obesity Unit, Department of Pediatrics and Adolescent Medicine, Ulm University, Eythstr. 24, D-89073, Ulm, Germany. 9. Department of Pediatric Endocrinology, Diabetes and Nutrition Medicine, Vestische Children's Hospital, University Witten/Herdecke, Dr. F. Steiner Str. 5, D-45711, Datteln, Germany.
Abstract
Type 2 diabetes can occur without any symptoms, and health problems associated with the disease are serious. Screening tests allowing an early diagnosis are desirable. However, optimal screening tests for diabetes in obese youth are discussed controversially. We performed an observational multicenter analysis including 4848 (2668 female) overweight and obese children aged 7 to 17 years without previously known diabetes. Using HbA1c and OGTT as diagnostic criteria, 2.4% (n = 115, 55 female) could be classified as having diabetes. Within this group, 68.7% had HbA1c levels ≥48 mmol/mol (≥6.5%). FPG ≥126 mg/dl (≥7.0 mmol/l) and/or 2-h glucose levels ≥200 mg/dl (≥11.1 mmol/l) were found in 46.1%. Out of the 115 cases fulfilling the OGTT and/or HbA1c criteria for diabetes, diabetes was confirmed in 43.5%. For FPG, the ROC analysis revealed an optimal threshold of 98 mg/dl (5.4 mmol/l) (sensitivity 70%, specificity 88%). For HbA1c, the best cut-off value was 42 mmol/mol (6.0%) (sensitivity 94%, specificity 93%). CONCLUSIONS: HbA1c seems to be more reliable than OGTT for diabetes screening in overweight and obese children and adolescents. The optimal HbA1c threshold for identifying patients with diabetes was found to be 42 mmol/mol (6.0%). What is Known: • The prevalence of obesity is increasing and health problems related to type 2 DM can be serious. However, an optimal screening test for diabetes in obese youth seems to be controversial in the literature. What is New: • In our study, the ROC analysis revealed for FPG an optimal threshold of 98 mg/dl (5.4 mmol/l, sensitivity 70%, specificity 88%) and for HbA1c a best cut-off value of 42 mmol/mol (6.0%, sensitivity 94%, specificity 93%) to detect diabetes. Thus, in overweight and obese children and adolescents, HbA1c seems to be a more reliable screening tool than OGTT.
Type 2 diabetes can occur without any symptoms, and health problems associated with the disease are serious. Screening tests allowing an early diagnosis are desirable. However, optimal screening tests for diabetes in obese youth are discussed controversially. We performed an observational multicenter analysis including 4848 (2668 female) overweight and obesechildren aged 7 to 17 years without previously known diabetes. Using HbA1c and OGTT as diagnostic criteria, 2.4% (n = 115, 55 female) could be classified as having diabetes. Within this group, 68.7% had HbA1c levels ≥48 mmol/mol (≥6.5%). FPG ≥126 mg/dl (≥7.0 mmol/l) and/or 2-h glucose levels ≥200 mg/dl (≥11.1 mmol/l) were found in 46.1%. Out of the 115 cases fulfilling the OGTT and/or HbA1c criteria for diabetes, diabetes was confirmed in 43.5%. For FPG, the ROC analysis revealed an optimal threshold of 98 mg/dl (5.4 mmol/l) (sensitivity 70%, specificity 88%). For HbA1c, the best cut-off value was 42 mmol/mol (6.0%) (sensitivity 94%, specificity 93%). CONCLUSIONS: HbA1c seems to be more reliable than OGTT for diabetes screening in overweight and obesechildren and adolescents. The optimal HbA1c threshold for identifying patients with diabetes was found to be 42 mmol/mol (6.0%). What is Known: • The prevalence of obesity is increasing and health problems related to type 2 DM can be serious. However, an optimal screening test for diabetes in obese youth seems to be controversial in the literature. What is New: • In our study, the ROC analysis revealed for FPG an optimal threshold of 98 mg/dl (5.4 mmol/l, sensitivity 70%, specificity 88%) and for HbA1c a best cut-off value of 42 mmol/mol (6.0%, sensitivity 94%, specificity 93%) to detect diabetes. Thus, in overweight and obesechildren and adolescents, HbA1c seems to be a more reliable screening tool than OGTT.
Authors: David C Ziemer; Paul Kolm; William S Weintraub; Viola Vaccarino; Mary K Rhee; Jennifer G Twombly; K M Venkat Narayan; David D Koch; Lawrence S Phillips Journal: Ann Intern Med Date: 2010-06-15 Impact factor: 25.391
Authors: G T Ko; J C Chan; V T Yeung; C C Chow; L W Tsang; J K Li; W Y So; H P Wai; C S Cockram Journal: Diabetes Care Date: 1998-08 Impact factor: 19.112
Authors: John B Buse; Francine R Kaufman; Barbara Linder; Kathryn Hirst; Laure El Ghormli; Steven Willi Journal: Diabetes Care Date: 2012-11-27 Impact factor: 19.112
Authors: Omoye E Imoisili; Elizabeth A Lundeen; David S Freedman; Lindsay S Womack; Jessica Wallace; Simon J Hambidge; Steven Federico; Rachel Everhart; Delia Harr; Jillian Vance; Lyudmyla Kompaniyets; Carrie Dooyema; Sohyun Park; Heidi M Blanck; Alyson B Goodman Journal: Acad Pediatr Date: 2020-12-03 Impact factor: 3.107
Authors: Jose Lopez-Lopez; Jennifer Garay; Edwin Wandurraga; Paul A Camacho; Fernando Higuera-Escalante; Daniel Cohen; Patricio Lopez-Jaramillo Journal: PLoS One Date: 2018-04-13 Impact factor: 3.240
Authors: P Di Bonito; M R Licenziati; D Corica; M G Wasniewska; A Di Sessa; E Miraglia Del Giudice; A Morandi; C Maffeis; M F Faienza; E Mozzillo; V Calcaterra; F Franco; G Maltoni; G Valerio Journal: J Endocrinol Invest Date: 2022-05-17 Impact factor: 5.467
Authors: Shanhu Qiu; Ziwei Du; Wei Li; Juan Chen; Hang Wu; Jingbao Liu; Min Cai; Bei Wang; Haijian Guo; Zilin Sun Journal: Ann Lab Med Date: 2020-06-17 Impact factor: 3.464